Paliperidone Palmitate Extended-Release Dosing Regimens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with schizophrenia face challenges in adhering to daily oral antipsychotic medication regimens, leading to symptom relapses, hospitalizations, and weight gain issues, particularly with long-acting injectable formulations like paliperidone palmitate, which require precise dosing schedules and lack flexibility.
Innovation Solution
The development of a paliperidone palmitate extended-release injectable suspension with a six-month dosing interval, allowing for administration up to two weeks before or three weeks after the scheduled date, and re-initiation dosing regimens for missed doses, along with a formulation to stabilize or decrease body weight, providing flexibility and improved adherence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a long-acting injectable formulation with extended dosing interval is used, then treatment adherence is improved, but dosing flexibility is reduced
Solution Approach 1:
The patent implements a dynamic dosing window that adapts to patient needs and clinical circumstances. The dosing interval is not fixed but allows flexibility within a defined window (e.g., administering doses between 4-8 months rather than exactly every 6 months), enabling the system to balance adherence improvement with necessary adaptability to individual patient situations.
2Reliability
If a fixed dosing schedule is maintained, then therapeutic plasma concentrations are maintained, but relapse risk increases when doses are missed
Solution Approach 1:
The patent establishes predetermined guidelines and protocols for managing missed doses before they occur. These include pre-defined action thresholds (e.g., if a dose is missed by more than X months, administer a make-up dose), allowing clinicians to quickly respond to missed doses without compromising therapeutic levels or increasing relapse risk.
Solution Approach 2:
The patent incorporates monitoring and feedback mechanisms to track dosing adherence and plasma concentrations. When missed doses are detected, the system provides feedback through established protocols that guide appropriate corrective actions, such as administering make-up doses or adjusting future dosing intervals, thereby maintaining therapeutic levels and preventing relapse.
3Quantity of substance
If traditional dosing regimens are used, then treatment coverage is adequate, but weight gain issues worsen
Solution Approach 1:
The patent utilizes extended-release formulations that modify the release parameters of the medication, providing sustained therapeutic levels over longer intervals. This parameter change in drug delivery kinetics maintains adequate treatment coverage while potentially reducing the metabolic burden and weight gain associated with more frequent dosing regimens.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces relapse risk, enhances treatment adherence, and mitigates weight gain issues, offering a more flexible and effective long-term treatment option for schizophrenia patients by maintaining therapeutic plasma concentrations and improving quality of life.
Implementation Method 1
paliperidone palmitate extended-release injectable suspension
Implementation Method 2
paliperidone esters such as paliperidone palmitate dissolve slowly after an intramuscular injection before being hydrolyzed to paliperidone and made available in the systemic circulation
Data Source
AI summary
The present invention provides a method of treating patients with long acting injectable paliperidone palmitate formulations.